HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Liver Cell Adenoma (Hepatocellular Adenoma)

Subscribe to New Research on Liver Cell Adenoma

A benign epithelial tumor of the LIVER.

Also Known As:

Hepatocellular Adenoma; Adenoma, Liver Cell; Adenomas, Hepatocellular; Adenomas, Liver Cell; Benign Hepatoma; Benign Hepatomas; Hepatocellular Adenomas; Hepatomas, Benign; Liver Cell Adenomas; Adenoma, Hepatocellular; Hepatoma, Benign

Networked: 453 relevant articles (8 outcomes, 20 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma)
2.	Carcinoma (Carcinomatosis)
3.	Neoplasms (Cancer)
4.	Focal Nodular Hyperplasia
5.	Adenoma (Adenomas)

Experts

1.	Bioulac-Sage, Paulette: 25 articles (01/2016 - 11/2003)
2.	Zucman-Rossi, Jessica: 21 articles (01/2016 - 11/2003)
3.	Balabaud, Charles: 19 articles (01/2016 - 11/2003)
4.	Rebouissou, Sandra: 9 articles (02/2013 - 09/2004)
5.	Nagano, Kasuke: 8 articles (10/2015 - 11/2004)
6.	Fukushima, Shoji: 8 articles (10/2015 - 11/2004)
7.	National Toxicology Program: 8 articles (10/2013 - 09/2004)
8.	Laurent, Christophe: 6 articles (01/2013 - 11/2003)
9.	Jeannot, Emmanuelle: 6 articles (02/2011 - 11/2003)
10.	Couchy, Gabrielle: 5 articles (01/2016 - 09/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Cell Adenoma:

1.	Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA 10/01/2014 - "Glutamine synthetase interpretation in hepatocellular adenoma." 08/01/2014 - "Diffuse glutamine synthetase overexpression restricted to areas of peliosis in a β-catenin-activated hepatocellular adenoma: a potential pitfall in glutamine synthetase interpretation." 01/01/2014 - "The majority of inflammatory hepatocellular adenomas demonstrated perivascular and/or patchy glutamine synthetase staining (73.6%), while the remaining cases had diffuse (7.5%), negative (3.8%), or patchy pattern of staining (15%) that showed subtle differences from the classic map-like staining pattern and was designated as pseudo map-like staining. " 01/01/2013 - "Value and limits of routine histology alone or combined with glutamine synthetase immunostaining in the diagnosis of hepatocellular adenoma subtypes on surgical specimens." 06/01/2011 - "We report a case of hepatocellular carcinoma arising within a pigmented telangiectatic hepatocellular adenoma in a noncirrhotic man with diffuse glutamine synthetase and nuclear β-catenin positivity. "
2.	Amyloid (Amyloid Fibrils)IBA 01/01/2014 - "Positive staining for serum amyloid-associated protein was seen in the majority of inflammatory hepatocellular adenomas (92.6%) and in the minority of focal nodular hyperplasia (17.5%). " 01/01/2014 - "Expression of serum amyloid-associated protein in inflammatory hepatocellular adenoma and map-like pattern of glutamine synthetase in focal nodular hyperplasia can be helpful in this distinction, but the pitfalls and limitations of these markers have not been established. " 01/01/2014 - "Our results highlight the diagnostic errors that can be caused by variant patterns of staining with glutamine synthetase and serum amyloid-associated protein in inflammatory hepatocellular adenoma and focal nodular hyperplasia. " 01/01/2014 - "Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma." 11/01/2011 - "Map-like pattern with glutamine synthetase in focal nodular hyperplasia and cytoplasmic staining with serum amyloid associated protein in inflammatory hepatocellular adenoma (HA) are useful for this distinction. "
3.	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 03/01/2001 - "Between 53 and 79 weeks of age, 39% of rats receiving N-nitrosodiethylamine alone developed multiple (1.5 +/- 0.8) hepatocellular adenomas. " 09/01/1992 - "Progressive atypia in spontaneous and N-nitrosodiethylamine-induced hepatocellular adenomas of C3H/HeNCr mice." 09/01/1995 - "Chemoprevention of diethylnitrosamine-induced liver foci and hepatocellular adenomas in C3H mice." 04/01/1991 - "Histochemical profile of mouse hepatocellular adenomas and carcinomas induced by a single dose of diethylnitrosamine." 05/01/1988 - "Animals were sacrificed at either 52 or 78 wk. PB and EPH significantly enhanced the development of hepatocellular foci and hepatocellular adenomas at 52 wk and hepatocellular carcinomas at 78 wk in N-nitrosodiethylamine-initiated rats. "
4.	Phenobarbital (Luminal)FDA Link 03/01/2001 - "Multiplicities of hepatocellular adenomas were significantly greater than the control value in rats fed 1,500 ppm DPH or 500 ppm phenobarbital (5.9 +/- 4.8 and 10.1 +/- 6.7, respectively), but not in the rats receiving 500 ppm DPH (2.3 +/- 1.6). " 06/01/2012 - "Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report." 04/01/2003 - "[Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital]." 05/01/1991 - "Higher body and carcass (body - liver) weights in sodium phenobarbital (PB) treated mice correlate with formation of multiple hepatocellular adenomas in yellow Avy/A and agouti A/a (C3H x VY) F1 hybrid male mice. " 01/01/1996 - "Chronic exposure to high doses of phenobarbital (PB) causes hepatocellular adenomas in both mice and rats and hepatocellular carcinomas in some strains of mice. "
5.	Ethanol (Ethyl Alcohol)IBA 02/28/2011 - "Chronic administration of ethanol leads to an increased incidence of hepatocellular adenoma by promoting H-ras-mutated cells." 01/01/2005 - "Ethanol induced a dose-dependent trend in hepatocellular adenoma or carcinoma in male mice, with the incidence being marginally increased at the highest dose. " 06/01/2011 - "Although ethanol feeding also resulted in significantly fewer altered hepatic foci, hepatocellular adenoma was detected in ethanol-fed rats at 10 mo, but not in control rats given the same dose of DEN. " 05/01/1991 - "The incidence of hepatocellular adenomas in the groups given 10 mg ethyl carbamate/kg was, as shown by chi-square analysis, significantly reduced by the ethanol and wine treatments. " 01/01/2001 - "We report a 20-year-old man with glycogen storage disease type Ia (GSD Ia) who presented multiple hepatocellular adenomas (HCAs) in 1993 and in whom percutaneous ethanol injection (PEI) was conducted as treatment for some enlarging tumors beneath the liver surface. "
6.	Fatty Acid-Binding ProteinsIBA 03/01/2014 - "As published in hepatocellular adenoma, multifocality and larger tumor size were more common in liver fatty acid-binding protein-negative noncirrhotic hepatocellular carcinoma. " 03/01/2009 - "In case of uncertainty, particularly with hepatocellular adenoma, additional immunostainings including liver fatty acid-binding protein, serum amyloid A and beta-catenin were performed. " 12/01/2011 - "The use of liver fatty acid binding protein (L-FABP), β-catenin, glutamine synthetase, serum amyloid protein and C-reactive protein is found to be helpful in the subtyping of hepatocellular adenomas. " 08/27/2014 - "Routine histology includes HE, trichrome and cytokeratin 7. Immunohistochemistry includes glutamine synthase and according to the above results additional markers such as liver fatty acid binding protein, C reactive protein and beta catenin may be realized to differentiate focal nodular hyperplasia from hepatocellular adenoma subtypes. "
7.	C-Reactive ProteinIBA 01/01/2010 - "Inflammatory hepatocellular adenoma (IHCA) defines a subgroup of hepatocellular adenomas characterized by the expression of members of the acute-phase inflammatory response [(serum amyloid A protein (SAA) and C-reactive protein (CRP)]. " 01/01/2016 - "The most frequent hepatocellular adenoma subtype, namely inflammatory adenoma, harbor somatic activating mutations of genes involved in the interleukin-6 pathway that lead to high C-reactive protein and serum amyloid A expression. " 12/01/2011 - "The use of liver fatty acid binding protein (L-FABP), β-catenin, glutamine synthetase, serum amyloid protein and C-reactive protein is found to be helpful in the subtyping of hepatocellular adenomas. " 08/27/2014 - "Routine histology includes HE, trichrome and cytokeratin 7. Immunohistochemistry includes glutamine synthase and according to the above results additional markers such as liver fatty acid binding protein, C reactive protein and beta catenin may be realized to differentiate focal nodular hyperplasia from hepatocellular adenoma subtypes. "
8.	Lamivudine (3TC)FDA Link 10/01/2013 - "In the high dose comparison, the incidences of hepatocellular adenoma in males in the AZT-H group and hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) in males in the AZT/3TC-H and AZT/3TC/NVP-H groups were significantly greater than those in the vehicle control group; the incidences of these lesions in the 3TC-H and NVP-H groups were significantly less than those in the AZT/3TC/NVP-H group. " 10/01/2013 - "There was clear evidence of carcinogenic activity of AZT in combination with 3TC, and AZT in combination with 3TC and NVP in male heterozygous F1 p53+/- mice based on increased incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined). " 10/01/2013 - "In the combination dose comparison, the incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) in the liver of all groups of males dosed with AZT/3TC/NVP were significantly increased compared to the vehicle control group. "
9.	Urethane (Ethyl Carbamate)IBA 05/01/1991 - "The incidence of hepatocellular adenomas in the groups given 10 mg ethyl carbamate/kg was, as shown by chi-square analysis, significantly reduced by the ethanol and wine treatments. " 05/01/1991 - "Both ethanol and wine treatments reduced the incidence of lung Clara-cell adenomas in mice given 10 mg ethyl carbamate/kg and reduced the frequency (number of specific tumours/number of tumour-bearing mice) of both Clara-cell adenomas in mice given 10 mg ethyl carbamate/kg and of alveolar adenomas in mice given 20 mg ethyl carbamate/kg. Wine treatments also reduced the frequency of hepatocellular adenomas compared with those of other treatment groups, and no hepatocellular carcinomas developed in any of the groups given wine, even with the 20-mg/kg ethyl carbamate dose. "
10.	Triprolidine (Actidil)FDA Link 04/01/1995 - "While there was a positive dose response trend for hepatocellular adenomas in males the combination of these and hepatocellular carcinomas eliminated the significant trend, and it was concluded that there was no evidence of a carcinogenic response to triprolidine in B6C3F1 mice.(ABSTRACT TRUNCATED AT 250 WORDS)"

Therapies and Procedures

1.	Liver Transplantation 05/01/2011 - "GSD represents an indication for liver transplantation (OLT) when medical treatment fails to control the metabolic dysfunction and/or there is an high risk of malignant transformation of hepatocellular adenomas (HCA). " 03/01/1995 - "The aim of this report is to describe the indications, feasibility, and outcome of liver transplantation for hepatocellular adenomas. " 03/01/1995 - "Liver transplantation for treatment of giant hepatocellular adenomas." 01/01/1998 - "This retrospective analysis deals with 58 patients who underwent surgery for hepatocellular adenoma: resection of different extension: n = 54, liver transplantation n = 4. In 39.6% of the patients the tumor was an incidental finding. " 03/01/1995 - "A 66-year-old man with a 17-cm hepatocellular adenoma originating in the left lobe but involving nearly the entire liver and a 35-year-old woman with a 20-cm tumor involving the right lobe of the liver and compressing the left lobe underwent liver transplantation without complication. "
2.	Injections 08/01/1979 - "All group I rats survived for more than 290 days after the start of injections, and 9 of 20 rats developed liver cell adenoma. " 03/19/1996 - "injections at a dose of 1600 nmol per mouse on 1, 8, and 15 days after birth developed 92 and 96% hepatocellular adenomas, and 100 and 83% hepatocellular carcinoma, respectively. " 04/01/1991 - "In continuation of earlier studies on murine neoplastic liver lesions, we characterized by histochemical methods the phenotype of hepatocellular adenomas and carcinomas induced by single injections of diethylnitrosamine (1.25, 2.5, or 5.0 micrograms/g of body weight) in 15-day-old C57BL/6 x male C3H F1 mice. "
3.	Contraception (Birth Control) 12/01/2006 - "Here we report the case of a 37-year-old FAP woman presenting a hepatocellular adenoma after oestroprogestative oral contraception use. " 02/01/1999 - "Multiple hepatocellular adenomas in a patient with a history of oral contraception." 11/01/1995 - "[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception]." 10/05/1992 - "[Hepatocellular adenoma after oral contraception]." 01/01/1977 - "The association between oral contraception and hepatocellular adenoma--a preliminary report."
4.	Hepatectomy 11/01/2014 - "A 54-year-old woman with multiple telangiectatic hepatocellular adenoma without degeneration (>5 cm) underwent laparoscopic right hepatectomy with the hanging maneuver. " 11/01/2014 - "Pure laparoscopic right hepatectomy with the hanging maneuver for multiple hepatocellular adenomas." 07/01/2007 - "Right hepatectomy with anterior approach for ruptured liver cell adenoma." 12/15/1984 - "Successful pregnancy following partial hepatectomy for removal of hepatocellular adenomas." 03/01/1961 - "Partial hepatectomy for benign hepatoma. "
5.	Cesarean Section (Caesarean Section) 03/01/2011 - "In four cases, hepatocellular adenomas grew during pregnancy, requiring a Caesarean section in one patient (two pregnancies) at 36 and 34 weeks because of an assumed high risk of rupture. " 01/01/1990 - "In the 35th week of a twin-pregnancy fatal bleeding to death due to liver-cell adenoma and rupture of liver capsule could not be prevented despite immediate caesarean section, enucleation of the adenoma and intensive treatment." 02/01/1982 - "A benign hepatic tumor (liver cell adenoma) was discovered accidentally during Cesarean section in a 32-year old woman who had been taking oral contraceptives (OCs) for 4 months prior to her pregnancy. "